Evidence map›Paper›PMID 31300969›Full record

Observational studyAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2020

Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study.

Christel Bruggmann, Juan F Iglesias, Marianne Gex-Fabry, Rachel Fesselet, Pierre Vogt, Farshid Sadeghipour, Pierre Voirol

Registry-linked trialOpen access · hybridAbstract readObservational Study
In one paragraph

Observational study in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01305785 (National Registry of Acute Myocardial Infarction in Switzerland), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01305785 unknown statusnot on this map

National Registry of Acute Myocardial Infarction in Switzerland

TypeobservationalSponsorLuzerner KantonsspitalRan1997Enrolled60,000ConditionsAcute Coronary Syndrome
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Optimal Medical Therapy Prescription in Patients with Acute Coronary Syndrome in the Netherlands: A Multicenter Pilot Registry.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Christel BruggmannService of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Christel.Bruggmann@chuv.ch.ORCID http://orcid.org/0000-0003-2919-8383
Juan F IglesiasService of Cardiology, Geneva University Hospital, Geneva, Switzerland.
Marianne Gex-FabryUniversity of Geneva, Geneva, Switzerland.
Rachel FesseletService of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Pierre VogtService of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Farshid SadeghipourService of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Pierre VoirolService of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
University of Geneva · CHUniversity of Lausanne · CHUniversity Hospital of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimAmerican and European associations of cardiology published specific guidelines about recommended drugs for secondary prevention in ST-segment elevation myocardial infarction (STEMI) patients. Our aim was to assess whether drug prescription for STEMI patients was in accordance with the guidelines at discharge and after 1 year.

methodWe used data of 361 patients admitted for STEMI in a tertiary hospital in Switzerland from 2014 to 2016. We assessed the adequacy of prescription of recommended drugs at two time points: discharge and after 1 year. Medications assessed were aspirin, P2Y12 inhibitors, statin, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) and β-blockers. We took into account several criteria like statin dosage (low versus high intensity) and presence of contraindication for consideration of optimal therapy. Predictors of incomplete prescription of guideline medications were then assessed with multivariate logistic regression models.

resultsFrom discharge (n = 358) to 1-year follow-up (n = 303), rate of optimal prescription was reduced from 98.6 to 91.7% for aspirin, from 93.9 to 79.1% for P2Y12 inhibitors, from 83.8 to 65.7% for statins, from 98.6 to 95.6% for ACEIs/ARBs, and from 97.1 to 96.9% for β-blockers. Predictors of incomplete prescription of guideline medications at discharge were female sex (odds ratio [OR] 2.54, p = 0.007), active or former smoker status (OR 2.29, p = 0.017), multivessel disease (OR 2.07, p = 0.022), left ventricular ejection fraction < 40% (OR 2.49, p = 0.008), and transfer to cardiac surgery (OR 9.66, p = 0.018). At 1 year, age > 65 (OR 1.92, p = 0.036) remained the only significant predictor.

conclusionThe present study showed a high prescription rate of guideline-recommended medications in a referral center for primary percutaneous coronary intervention. At discharge, women and co-morbid patients were at the highest risk of incomplete prescription of guideline medications, whereas long-term prescription was suboptimal for elderly. A drug lacking at time of discharge was rarely introduced within the year, which underscores the paramount importance of optimal prescription at time of discharge. Strategies like implementing a standardized prescription could reduce the proportion of suboptimal prescription. It could therefore be one way to improve the long-term quality of care of our patients to the highest level. This study used local data from AMIS Plus-National Registry of Acute Myocardial Infarction in Switzerland (NCT01305785).

Indexed as

Adrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAspirinCardiovascular AgentsDrug PrescriptionsFemaleFollow-Up StudiesGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMiddle AgedMyocardial InfarctionPrescription DrugsProspective StudiesAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAspirinCardiovascular AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsPrescription Drugs

Identifiers

PMID31300969
PMCPMC6978447
OpenAlexW2959845016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.